J Antimicrob Chemother 2004, 53:808–13.PubMedCrossRef 8. Montesinos I, Delgado T, Riverol D, Salido E, Miquel MA, Jimenez A, Sierra A: Changes in the epidemiology of methicillin-resistant S. aureus associated with the emergence of EMRSA-16 at a university hospital. J Hosp Infect 2006, 64:257–63.PubMedCrossRef SC79 price 9. Vindel A, Trincado P, Gomez E, Cabrera R, Boquete T, Sola C, Valdezate S, Saez-Nieto JA: Prevalence and evolution of methicillin-resistant Staphylococcus aureus in Spanish hospitals between 1996 and 2002. J Clin Microbiol 2006, 44:266–70.PubMedCrossRef 10. Witte W, Braulke C, Cuny C, Heuck D, Kresken M: Changing pattern of antibiotic resistance
in methicillin-resistant Staphylococcus aureus from German hospitals. Infect Control Hosp Epidemiol 2001, 22:683–86.PubMedCrossRef 11. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement M100-S17. CLSI, Wayne, PA, USA; 2007. 12. Aboshkiwa M, Rowland G, Coleman G: Nucleotide sequence of the Staphylococcus aureus RNA polymerase rpoB gene and comparison of its predicted
amino acid sequence with those of other bacteria. Biochem 1995, 1262:73–78. 13. Aubry-Damon H, Soussy CJ, Courvalin P: Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus . Antimicrob Agents Chemother 1998, 42:2590–94.PubMed 14. Zimmerli W, Widmet AF, Blatter M, Frei R, Ochsner PE: Role of rifampin for treatment of orthopedic implant-related staphylococcal infections. JAMA 1998, 279:1537–41.PubMedCrossRef 15. CA4P molecular weight Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Temsirolimus in vivo Raoult D: Oral treatment of Staphylococcus spp. infected orthopedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997, 39:235–40.PubMedCrossRef 16. Moellering RC: Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008, 46:1032–37.PubMedCrossRef 17. Wichelhaus TA, Shäfer V, Brade V, Böddinghaus B: Molecular
characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 1999, 43:2813–16.PubMed selleck products 18. Heym B, Le Moal M, Armand-Lefevre L, Nicolas-Chanoine MH: Multilocus sequence typing (MLST) shows that the ‘Iberian’ clone of methicillin-resistant Staphylococcus aureus has spread to France and acquired reduced susceptibility to teicoplanin. J Antimicrob Chemother 2002, 50:323–29.PubMedCrossRef 19. Oliveira DC, Tomasz A, De Lencastre H: The evolution of pandemic clones of methicillin resistant Staphylococcus aureus : identification of two ancestral genetic backgrounds and the associated mec elements. Microb Drug Resist 2001, 7:349–61.PubMedCrossRef 20.
No related posts.